About this trial
COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system
Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level:
In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals.
Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.
Eligibility criteria
Qualifiers
PCR-confirmed SARS-CoV-2 infection
living in one of the target areas
age at least 18 years
written informed consent
Disqualifiers
Acute SARS-CoV-2 infection or reinfection
Trial design
Treatments tested in this trial
- Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Treatment groups
Sponsors and collaborators
University Hospital Schleswig-Holstein
Lead sponsor
Charite University, Berlin, Germany
Collaborator
Wuerzburg University Hospital
Collaborator
German Federal Ministry of Education and Research
Collaborator